Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
GRI Bio Inc
GRI
Healthcare
Biotechnology
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis...
. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GRI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 16, 2025 8:35am
New Press Release - GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 02, 2025 4:05pm
New Press Release - GRI Bio Announces Closing of $5.0 Million Public Offering
LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the...
read article.
(103)
•••
Iseneschal
X
Comment by
Iseneschal
on Apr 02, 2025 12:18pm
RE:GRI....N.L.O.D $2.01
And you thought I was full of **it ; )
(103)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 01, 2025 2:20pm
GRI....N.L.O.D $2.01
Mr. M is still workin it .....injecting your soul with Hopium This is dead
(103)
•••
Iseneschal
X
Comment by
Iseneschal
on Apr 01, 2025 1:37pm
RE:GRI....This done
LMFBO.......... $2.44 down and red on over 11 million shares Told ya
(103)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 01, 2025 12:36pm
GRI....This done
Moving on
(103)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 01, 2025 12:19pm
GRI....now all the DT'ers are on Hopium
Mr. M will keep u guessing till your completely spent
(103)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 01, 2025 12:16pm
GRI....These Maddapakkas got just what they wanted
Bury all The Greater Fools with high priced paper You've all been had again ...What a f'king game!!!!
(103)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 01, 2025 12:05pm
GRI....Tah Dah...oop der id is ; ))))
Red as a beet
(103)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 01, 2025 11:59am
GRI....I predict a Green to Red move ; )
Wait for it LoL
(103)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 01, 2025 11:58am
GRI....now trading at $3.33 after the P.O announcement
Tell me ....r u going back up to $11 before the close??? Not in this "lifetime"
(103)
•••
Iseneschal
X
Comment by
Iseneschal
on Apr 01, 2025 11:57am
RE:Buy buddy buy because it's taking off this morning.Wow
LoL.....You've all been had AGAIN !!!! P.O set up....the Maggot buried all the Chasers in the 1st 10 mins of Regular hours trading..... GRI Bio Announces Pricing of $5.0 Million Public
...more
(214)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Apr 01, 2025 9:43am
Buy buddy buy because it's taking off this morning.Wow
Wow,this stock is flying today,so that you guys should be getting on-board with it already
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2024 4:20pm
New Press Release - GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker studyTopline data of GRI-0621 readout expected in Q2 2025Currently available treatments for IPF are limited with...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 24, 2024 8:30am
New Press Release - GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)Current treatment options for IPF are limited with only 2...
read article.
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
How Web3 Will Fundamentally Reshape Finance
This company is set to benefit from a change in Ontario legislation
Largest integrated facility services provider in Canada releases financial results for Q1, 2025